Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-trial access roll-over study of ribociclib in HR+, HER2- advanced or metastatic breast cancer
2021-005184-42Phase 4Active
- Sponsor
- Novartis
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ribociclib in breast cancer, sponsored by Novartis. Primary endpoint: Percentage of participants with treatment-emergent adverse events (AEs). Started Feb 2022; status: active.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2021-005184-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005184-42.